Rheumatologist - pharmacist co-management of MTX initiators @GeisingerHealth Philadelphia Having the dual skill set actually helped with adherence to guidelines vs standard care. Would be great to see how this works with implementation in RA clinics #ACR23 ABST2484 @RheumNow https://t.co/88R1BYzYn5

#ACR23 Abstr# 2490 Data supporting aggressive early treatment in #SLE? Multicentre open label RCT in China showed low dose MMF + Pred 0.5mg/kg/d reduced severe flare & lupus nephritis cases vs HCQ + Pred in new onset SLE with high dsDNA but w/o major organ involvement @RheumNow https://t.co/oRlgCaOvXo

Watch: Utility of AI and ChatGPT in Rheumatology Dr. Kathryn Dao interviews Dr. Richard Stern at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23 https://t.co/SH0TGAdvm8 https://t.co/RHu8bH9YOG

TM86 #ACR23 @RheumNow Auricular chondritis, arthritis, axonopathy, high inflamm. Initial Dx: RP Exam: lymphadenopathy, erythema nodosum, TJC 36, SJC 4 (knees/ankles), decr sensation, asymm reflex, macular rash, nerve thicken Skin bx: septal panniculitis wo vasc Dx: leprosy https://t.co/P5QJArRDaA

#Cardiovascular imaging will help to detect #cardiac abnormalities earlier@in #rheumatic #diseases. #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ 14T118 https://t.co/QKCpLWtkUv

🚩Adjunct therapy to treat vasculopathy of MDA5-DM ⭐️Botox heals digital ulcerations and improves Raynaud's (slide 1) Dr. Katherine Shaw injects Botox for healing recalcitrant ulcerated Gottron's papules (example patient failed nifedipine, sildenafil, pentoxyfylline & while on… https://t.co/4XCvRrzeTL https://t.co/yxUCzS30W1

What do we know about IL1 drugs in #OA only a small few stidies prior to CANTOS . COLCHCINE didnt seem to work LoDoCO2 post hoc analysis may work? @RheumNow #ACR23 https://t.co/h4oVRppI5S

Gene signature predicts RA trajectory during pregnancy: Blood RNAseq *before* pregnancy 🚺 improve during preg: Strong Neutrophil signature 🚺 experience dis worsening: Strong B cell signature Needs replication but could have major implications! @RheumNow #ACR23 ABST2481 https://t.co/gOHwEvOOM6

#ACR23 Abstr# 2487 How to reduce PBO response in #SLE trials? Try adding low dose GC as co-primary endpoint. Interim analysis of Phase 2 RCT: SRI-4 + sustained GC dose to ≤5mg/d or ≤BL from Wk16 to 28 was met more in Ianalumab (BAFF-R-i) vs PBO (44% vs 9%) @RheumNow https://t.co/JEnMWKilR6

TM85 #ACR23 @RheumNow IPF s/p lung transplant p/w diffuse bone pain Exam: no synovitis, +crackles. Labs: ALP 203 CT chest: stable mycetoma Xray: periosteal reaction Dx: vericonazole periosititis Positive Mucorales PCR, fluoride level 19 (ref <4) Bone pain improved stopping voric https://t.co/Gt8mOAssvh

Anti-fibrotics in RA-ILD Retro analysis of 74 pts AEs frequent 55% and discontinuation in 46% (more than in initial RCTs) No diff between AF FCV trajectory mildly improved ABST2479 @RheumNow @Juge_P_A @PhilippeDieude #ACR23 https://t.co/GqsHxkIFgD

Rashes in Rheumatology at #ACR23 Which disease entity are these palms pathognomonic for? @RheumNow https://t.co/NmT1LTzWmm